Myeloid/lymphoid neoplasm associated with JAK2 rearrangement
MONDO:0035121Also known as: myeloid/lymphoid neoplasms with PCM1-JAK2
1844 clinical trials for this condition and its sub-types, 2 tagged with Myeloid/lymphoid neoplasm associated with JAK2 rearrangement itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare blood disorder: drug targets overactive immune cells
Disease control OngoingThis phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Cancer drug shows promise in taming rare blood disorder
Disease control OngoingThis study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES), a rare condition that can damage organs. About 70 adults and children (age 2 and up) with a specific form…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC